FathomX

FathomX is a digital health AI company based in Singapore, focused on advanced medical imaging solutions for breast cancer screening. It was established as a spin-off from the National University of Singapore and the National University Health System, founded by experts including Prof Mikael Hartman and Prof Feng Meng Ling. The company's main product, FxMammo, is an AI-powered assistant that enhances the accuracy of mammogram screenings by reducing false positive and false negative rates. FxMammo streamlines clinical workflows, decreasing the time needed for mammogram assessments and minimizing the number of radiologists required per screening. The technology is backed by over three years of research and has received regulatory approvals in Singapore and Thailand, with plans for expansion into other countries. FathomX is actively involved in joint research collaborations, including work with Japan’s National Cancer Center, to develop new medical devices for mammary gland diseases. The company has raised SGD 2.24 million in Pre-Series A funding to support its growth and commercialization efforts in the Asia Pacific region.

• Employees 16
• Founded 2019
• Total Funding $1603365